KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lam Research (LRCX) EBT (2016 - 2026)

Lam Research has reported EBT over the past 18 years, most recently at $2.0 billion for Q1 2026.

  • Quarterly EBT rose 30.9% to $2.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.5 billion through Mar 2026, up 40.36% year-over-year, with the annual reading at $6.0 billion for FY2025, 36.65% up from the prior year.
  • EBT was $2.0 billion for Q1 2026 at Lam Research, up from $1.8 billion in the prior quarter.
  • Over five years, EBT peaked at $2.0 billion in Q1 2026 and troughed at $863.6 million in Q2 2023.
  • The 5-year median for EBT is $1.3 billion (2024), against an average of $1.4 billion.
  • Biggest five-year swings in EBT: tumbled 38.02% in 2023 and later surged 54.11% in 2025.
  • Tracing LRCX's EBT over 5 years: stood at $1.7 billion in 2022, then plummeted by 34.2% to $1.1 billion in 2023, then rose by 24.02% to $1.3 billion in 2024, then soared by 36.23% to $1.8 billion in 2025, then grew by 9.53% to $2.0 billion in 2026.
  • According to Business Quant data, EBT over the past three periods came in at $2.0 billion, $1.8 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.